Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach

被引:65
作者
Cooper, NJ
Sutton, AJ
Abrams, KR
Turner, D
Wailoo, A
机构
[1] Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England
[2] Univ Sheffield, ScHARR, Sheffield S10 2TN, S Yorkshire, England
关键词
Bayesian methods; cost-effectiveness analysis; decision models; meta-analysis; Markov chain Monte Carlo;
D O I
10.1002/hec.804
中图分类号
F [经济];
学科分类号
02 ;
摘要
Decision analytical models are widely used in economic evaluation of health care interventions with the objective of generating valuable information to assist health policy decision-makers to allocate scarce health care resources efficiently. The whole decision modelling process can be summarised in four stages: (i) a systematic review of the relevant data (including meta-analyses), (ii) estimation of all inputs into the model (including effectiveness, transition probabilities and costs), (iii) sensitivity analysis for data and model specifications, and (iv) evaluation of the model. The aim of this paper is to demonstrate how the individual components of decision modelling, outlined above, may be addressed simultaneously in one coherent Bayesian model (sometimes known as a comprehensive decision analytical model) and evaluated using Markov Chain Monte Carlo simulation implemented in the specialist software WinBUGS. To illustrate the method described, it is applied to two illustrative examples: (1) The prophylactic use of neurominidase inhibitors for the prevention of influenza. (2) The use of taxanes for the second-line treatment of advanced breast cancer. The advantages of integrating the four stages outlined into one comprehensive decision analytical model, compared to the conventional 'two-stage' approach, are discussed. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:203 / 226
页数:24
相关论文
共 80 条
  • [51] Docetaxel in the community setting:: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere®) in the UK
    O'Brien, MER
    Leonard, RC
    Barrett-Lee, PJ
    Eggleton, SPH
    Bizzari, JP
    [J]. ANNALS OF ONCOLOGY, 1999, 10 (02) : 205 - 210
  • [52] Bayesian cost-effectiveness analysis from clinical trial data
    O'Hagan, A
    Stevens, JW
    Montmartin, J
    [J]. STATISTICS IN MEDICINE, 2001, 20 (05) : 733 - 753
  • [53] Monitoring of large randomised clinical trials: a new approach with Bayesian methods
    Parmar, MKB
    Griffiths, GO
    Spiegelhalter, DJ
    Souhami, RL
    Altman, DG
    van der Scheuren, E
    [J]. LANCET, 2001, 358 (9279) : 375 - 381
  • [54] Assessing uncertainty in cost-effectiveness analyses: Application to a complex decision model
    Parmigiani, G
    Samsa, GP
    Ancukiewicz, M
    Lipscomb, J
    Hasselblad, V
    Matchar, DB
    [J]. MEDICAL DECISION MAKING, 1997, 17 (04) : 390 - 401
  • [55] PHARMIGIANI G, 2002, MODELING MED DECISIO
  • [56] Prevost TC, 2000, STAT MED, V19, P3359, DOI 10.1002/1097-0258(20001230)19:24<3359::AID-SIM710>3.0.CO
  • [57] 2-N
  • [58] Raiffa H., 2000, Applied statistical decision theory
  • [59] Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: Application to treatment of acute ischemic stroke
    Samsa, GP
    Reutter, RA
    Parmigiani, G
    Ancukiewicz, M
    Abrahamse, P
    Lipscomb, J
    Matchar, DB
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (03) : 259 - 271
  • [60] Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy
    Sendi, PP
    Craig, BA
    Meier, G
    Pfluger, D
    Gafni, A
    Opravil, M
    Battegay, M
    Bucher, HC
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (06) : 811 - 817